Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

• Status: Completed
• Trial end date: 1999-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Steno Diabetes Center; Steno Diabetes Center Copenhagen
• Collaborator: Bayer
• Treatments: Lisinopril; Nisoldipine

Criteria

Inclusion Criteria:

• diabetic nephropathy, type 1 diabetes, hypertension

Exclusion Criteria:

• child bearing potential, non-diabetic kidney disease, malignancy